Maintaining stability and security in investment portfolios is vital in an adverse macroeconomic environment. For instance, the current higher-for-longer interest rate environment coupled with other volatile macro elements may lead stocks into an unexpected and sudden downfall.Therefore, investors often seek out recession-proof stocks when escaping turbulent financial markets. These stocks have fundamentals that allow them to survive and flourish during difficult times — a fundamental and progressive resili ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $145.97, denoting a -1.24% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 1.19%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 1.96%.The the stock of world's biggest maker of health care products has fallen by 0.62% in the past month, lagging the Medical sector's gain of 3.54% and the S&P 500's gain of 3.35%.The investment community will ...

Johnson & Johnson (JNJ) announced that it has submitted a supplemental new drug application (sNDA) seeking expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States.Prezcobix is a two-drug fixed-dose combination tablet for treating HIV-1 infection in treatment-naïve and treatment-experienced adults and adolescent patients weighing at least 40 kg. It combines darunavir, J&J’s HIV-1 protease inhibitor, and cobicistat, Gilead Sciences’ (GILD) CYP3A inhibitor. J&J markets darunavir as ...

Johnson & Johnson (JNJ) announced positive topline results from the pivotal late-stage MDD3001 study, which evaluated its investigational oral drug seltorexant in patients with major depressive disorder (MDD) with insomnia symptoms.The MDD3001 study evaluated the drug as an adjunctive treatment to baseline antidepressants in adult and elderly patients who did not benefit from antidepressants alone. The study met all its primary and secondary endpoints.Treatment with seltorexant achieved statistically signif ...

NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       ...

Johnson & Johnson (NYSE:JNJ) Bernstein's 40th Annual Strategic Decisions Conference Call May 29, 2024 1:30 PM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright Okay. Thanks, everybody. Welcome back from lunch. I'm Lee Hambright, US MedTech Analyst at Bernstein. And we are thrilled to host Johnson & Johnson's Chairman and CEO, Joaquin Duato. Thank you so much for being here. Joaquin Duato Thank you. Lee Hambright ...

Johnson & Johnson (JNJ) announced a definitive agreement with Swiss biotech Numab Therapeutics to acquire global rights to NM26, a phase II-ready bispecific antibody for atopic dermatitis (“AD”). To execute the deal, Numab Therapeutics will spin off its wholly-owned subsidiary called Yellow Jersey Therapeutics, which holds NM26 rights, to its shareholders. J&J will acquire Yellow Jersey Therapeutics from Numab’s shareholders for a purchase price of $1.25 billion in cash.AD is a common inflammatory disease c ...

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab's pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Numab), a clin ...

In the latest trading session, Johnson & Johnson (JNJ) closed at $146.97, marking a -1.82% move from the previous day. This move lagged the S&P 500's daily gain of 0.7%. On the other hand, the Dow registered a gain of 0.01%, and the technology-centric Nasdaq increased by 1.1%.The the stock of world's biggest maker of health care products has risen by 1.96% in the past month, lagging the Medical sector's gain of 3.27% and the S&P 500's gain of 4.03%.Market participants will be closely following the financial ...

In today’s uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty. These massive companies in the industry provide defensive equities that are attractive buys for investors looking to strengthen their holdings. The first one shows substantial expansion in margins and profit growth. As a fundamental requirement, its diverse range of medical equipment and medic ...